Benzinga's Top #PreMarket Gainers

shares rose 19.02 percent to $2.19 in pre-market trading after the company announced the sale of its XTRAC & VTRAC businesses to MELA Sciences Inc

for $42.5 million in cash. The company also reported that it has paid off in full all outstanding debt.

gained 8.36 percent to $6.35 in pre-market trading after the company reported the FDA authorization of first-in-human clinical trial with AstraZeneca's Aurora B Kinase inhibitor Accurin AZD2811.

shares climbed 7.33 percent to $16.84 in pre-market trading after dropping 6.77 percent on Monday.

shares rose 6.23 percent to $73.70 in pre-market trading following strong earnings report and potential REIT separation.

shares climbed 5.33 percent to $9.69 in pre-market trading after the company reported results for its fiscal first quarter.